The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO TAT 2022 | Current therapeutic landscape for small-cell lung cancer
Triparna Sen, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the current therapeutic landscape for small-cell lung cancer (SCLC), including the epidemiology and mortality rates, likely causes, and current treatment options. First-line standard of care (SOC) is anti-PD-L1 immunotherapy combined with chemotherapy, with second-line SOC including topotecan. This interview was conducted at the virtual European Society for Medical Oncology Targeted Anti-Cancer Therapies (ESMO TAT) Congress 2022.
